Medifast Reports Steep Annual Revenue Decline and Net Loss for 2025, Citing GLP-1 Impact and Coach Network Contraction

summarizeSummary

Medifast's 2025 annual report reveals a significant 36% revenue drop and a shift to a net loss, driven by a sharp decline in its coach network and competitive pressures from GLP-1 weight loss medications.

check_boxKey Events

• Significant Annual Revenue Contraction

  Annual revenue decreased 36.0% to $385.8 million in 2025 from $602.5 million in 2024, primarily due to a decline in active coaches.

• Shift to Net Loss

  The company reported a net loss of $18.7 million ($1.70 per diluted share) in 2025, a significant reversal from a net income of $2.1 million in 2024.

• Sharp Decline in Coach Network

  The total number of active earning coaches decreased by 40.6% to 16,100 at December 31, 2025, compared to 27,100 at December 31, 2024, driven by challenges including GLP-1 medication adoption.

• Increased Tax Valuation Allowance

  An additional $12.1 million valuation allowance was recorded on deferred tax assets in 2025, reflecting management's assessment of future profitability.

auto_awesomeAnalysis

Medifast's 2025 annual report confirms a significant deterioration in financial performance, with a substantial revenue decline and a shift to a net loss. This follows the negative Q4 2025 results and weak 2026 outlook announced in a concurrent 8-K filing. The sharp contraction in the active coach network, a core component of its direct-selling model, is a critical operational challenge, exacerbated by the increasing adoption of GLP-1 weight loss medications. The company's decision to record an additional $12.1 million valuation allowance on deferred tax assets signals management's expectation of insufficient future taxable income, further highlighting profitability concerns. This comprehensive annual filing underscores the severe headwinds Medifast faces in a rapidly evolving market, with the stock already trading near its 52-week lows.